CHAPTER 1. INTRODUCTION
1.1. Market Definition
1.2. Executive Summary
1.3. The Scope of the Study
CHAPTER 2. RESEARCH METHODOLOGY
2.1. Secondary Research
2.2. Primary Research
2.3. Analytic Tools and Model
2.4. Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5. Expert Validation
2.6. Study Timeline
CHAPTER 3. MARKET ANALYSIS
3.1. Industry Value Chain Analysis
3.2. Porter's Five Force Analysis
3.2.1. Bargaining Power of Buyers
3.2.2. Bargaining Power of Suppliers
3.2.3. Threats of Substitutes
3.2.4. Threats of New Entrants
3.2.5. Degree of Competition
3.3. PESTLE Analysis
3.3.1. Political
3.3.2. Economical
3.3.3. Social
3.3.4. Technological
3.3.5. Legal
3.3.6. Environmental
3.4. SWOT Analysis
3.4.1. Strengths
3.4.2. Weakness
3.4.3. Opportunities
3.4.4. Threats
3.5. Y-O-Y Analysis
CHAPTER 4. MARKET DYNAMICS
4.1. Market Drivers
4.1.1. Increasing application areas of genomics
4.1.2. Reducing sequencing costs
4.1.3. Increasing government funding and growth in the number of genomics projects
4.1.4. Entry of new players and start-ups in the genomics market
4.2. Market Restraints & Challenges
4.2.1. Lack of trained professionals
4.2.2. Increasing the cost of equipment used in genomics
4.3. Market Opportunities
4.3.1. Use of genomics in specialised/ personalised medicine
4.3.2. Emerging economies
CHAPTER 5. GLOBAL GENOMICS MARKET – BY PROCESS
5.1. Introduction
5.2. Data analysis
5.3. Library preparation
5.4. Sequencing
CHAPTER 6. GLOBAL GENOMICS MARKET – BY TECHNOLOGY
6.1. Introduction
6.2. PCR
6.3. Microarray
6.4. Sequencing
6.5. Nucleic acid extraction and purification
6.6. Other technologies
CHAPTER 7. GLOBAL GENOMICS MARKET - BY PRODUCT AND SERVICE
7.1. Introduction
7.2. Consumables
7.3. Services
7.4. Instruments
CHAPTER 8. GLOBAL GENOMICS MARKET - BY APPLICATION
8.1. Introduction
8.2. Drug discovery and development
8.3. Agriculture &animal research
8.4. Precision medicine
8.5. Diagnostics
8.5.1. Cancer diagnostics
8.5.2. Monogenic (mendelian) disorders
8.5.3. Other diagnostic applications
8.5.3.1. Common diseases and complex disorders
8.5.3.2. Movement disorders
8.5.3.3. HIV
8.6. Other Applications
GLOBAL 9. GENOMICS MARKET - BY END USER
9.1. Introduction
9.2. Hospitals and clinics
9.3. Pharmaceutical & biotechnology companies
9.4. Research centres
9.5. Academic & government institutes
9.6. Other end users
CHAPTER 10. GLOBAL GENOMICS MARKET - BY GEOGRAPHY
10.1. Introduction
10.2. North America
10.2.1. U.S.
10.2.2. Canada
10.2.3. Mexico
10.2.4. Costa Rica
10.3. South America
10.3.1. Brazil
10.3.2. Argentina
10.3.3. Chile
10.3.4. Columbia
10.3.5. Others
10.4. Europe
10.4.1. U.K.
10.4.2. Germany
10.4.3. France
10.4.4. Italy
10.4.5. Spain
10.4.6. Russia
10.4.7. Netherlands
10.4.8. Switzerland
10.4.9. Poland
10.4.10. Others
10.5. APAC
10.5.1. China
10.5.2. Japan
10.5.3. India
10.5.4. South Korea
10.5.5. Australia & New Zealand
10.5.6. Malaysia
10.5.7. Singapore
10.5.8. Others
10.6. Middle East & Africa
10.6.1. UAE
10.6.2. Saudi Arabia
10.6.3. Iran
10.6.4. Iraq
10.6.5. Qatar
10.6.6. South Africa
10.6.7. Algeria
10.6.8. Morocco
10.6.9. Nigeria
10.6.10. Egypt
10.6.11. Others
CHAPTER 11. GLOBAL GENOMICS MARKET - COMPANY PROFILES
11.1. Thermo Fisher Scientific, Inc.
11.2. Agilent Technologies Inc.
11.3. Qiagen N.V.
11.4. Bio-Rad Laboratories.
11.5. Illumina, Inc.
11.6. F. Hoffmann-La Roche Ltd.
11.7. Bayer Healthcare LLC.
11.8. PerkinElmer Inc.
11.9. Ge Healthcare.
11.10. Pacific Biosciences of California, Inc.
11.11. Myriad Genetics Inc.
11.12. Luminex Corporation.
11.13. Danaher Corporation.
11.14. EuroClone S.p.A.
11.15. Irvine Scientific Sales Company, Inc.
CHAPTER 12. GLOBAL GENOMICS MARKET - COMPETITIVE LANDSCAPE
12.1. Market Share Analysis
12.2. Strategies adopted by top companies
12.3.Mergers, Acquisitions, Collaborations & Agreements
CHAPTER 13. MARKET INSIGHTS
13.1. Industry Experts Insights
13.2. Analysts Opinions
13.3. Investment Opportunities
CHAPTER 14. APPENDIX
14.1. List of Tables
14.2. List of Figures
